Shruti Gupta1,2, Sharon G Curhan1, Karen J Cruickshanks3,4, Barbara E K Klein4, Ronald Klein4, Gary C Curhan1,2,5,6. 1. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Madison, Wisconsin, U.S.A. 2. Renal Division, Department of Medicine, Brigham and Women's Hospital, Madison, Wisconsin, U.S.A. 3. Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, U.S.A. 4. Department of Ophthalmology and Visual Sciences, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, U.S.A. 5. Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, Massachusetts. 6. Harvard Medical School, Boston, Massachusetts.
Abstract
OBJECTIVES: There is a strikingly high prevalence of sensorineural hearing loss among patients with chronic kidney disease, with estimates ranging from 36% to 77%; however, longitudinal data are limited. We assessed whether lower baseline estimated glomerular filtration rate calculated using creatinine (eGFRCr ), as well as decline in eGFRCr over time, were associated with incident hearing loss. METHODS: Serum creatinine was measured in 1,843 individuals aged 48 to 80 years without hearing loss at the start of the Epidemiology of Hearing Loss Study in 1993. Follow-up creatinine assessments were conducted at 5 (n = 1,526) and 10 (n = 1,095) years. Hearing tests were conducted at baseline and at 5-, 10-, and 15-year follow-up visits. The risk of hearing loss was assessed as a function of baseline eGFRCr as well as a function of a 20% decline in eGFRCr between baseline and 5 years and between 5 and 10 years. Cox proportional hazards regression was used to examine the risk of incident speech-frequency hearing loss, defined as pure tone average (PTA) > 25 decibels hearing loss for thresholds at 0.5, 1, 2, and 4 kHz (PTA0.5,1,2,4 ) in either ear. RESULTS: During 15,676 person-years of follow up, there were 802 cases of incident hearing loss. There was no statistically significant association between lower baseline eGFRCr and risk of incident hearing loss. Decline in eGFRCr was also not associated with incident hearing loss at speech frequencies. CONCLUSION: Overall, there was no significant association between eGFRCr or decline in eGFRCr using the serum creatinine-based equation and risk of incident hearing loss. LEVEL OF EVIDENCE: 2 Laryngoscope, 130:E213-E219, 2020.
OBJECTIVES: There is a strikingly high prevalence of sensorineural hearing loss among patients with chronic kidney disease, with estimates ranging from 36% to 77%; however, longitudinal data are limited. We assessed whether lower baseline estimated glomerular filtration rate calculated using creatinine (eGFRCr ), as well as decline in eGFRCr over time, were associated with incident hearing loss. METHODS: Serum creatinine was measured in 1,843 individuals aged 48 to 80 years without hearing loss at the start of the Epidemiology of Hearing Loss Study in 1993. Follow-up creatinine assessments were conducted at 5 (n = 1,526) and 10 (n = 1,095) years. Hearing tests were conducted at baseline and at 5-, 10-, and 15-year follow-up visits. The risk of hearing loss was assessed as a function of baseline eGFRCr as well as a function of a 20% decline in eGFRCr between baseline and 5 years and between 5 and 10 years. Cox proportional hazards regression was used to examine the risk of incident speech-frequency hearing loss, defined as pure tone average (PTA) > 25 decibels hearing loss for thresholds at 0.5, 1, 2, and 4 kHz (PTA0.5,1,2,4 ) in either ear. RESULTS: During 15,676 person-years of follow up, there were 802 cases of incident hearing loss. There was no statistically significant association between lower baseline eGFRCr and risk of incident hearing loss. Decline in eGFRCr was also not associated with incident hearing loss at speech frequencies. CONCLUSION: Overall, there was no significant association between eGFRCr or decline in eGFRCr using the serum creatinine-based equation and risk of incident hearing loss. LEVEL OF EVIDENCE: 2 Laryngoscope, 130:E213-E219, 2020.
Authors: A R Antonelli; F Bonfioli; V Garrubba; M Ghisellini; M P Lamoretti; P Nicolai; C Camerini; R Maiorca Journal: Acta Otolaryngol Suppl Date: 1990
Authors: Carmen A Peralta; Michael G Shlipak; Suzanne Judd; Mary Cushman; William McClellan; Neil A Zakai; Monika M Safford; Xiao Zhang; Paul Muntner; David Warnock Journal: JAMA Date: 2011-04-11 Impact factor: 56.272
Authors: Linda F Fried; Ronit Katz; Mark J Sarnak; Michael G Shlipak; Paulo H M Chaves; Nancy Swords Jenny; Catherine Stehman-Breen; Dan Gillen; Anthony J Bleyer; Calvin Hirsch; David Siscovick; Anne B Newman Journal: J Am Soc Nephrol Date: 2005-10-26 Impact factor: 10.121
Authors: Michael G Shlipak; Mark J Sarnak; Ronit Katz; Linda F Fried; Stephen L Seliger; Anne B Newman; David S Siscovick; Catherine Stehman-Breen Journal: N Engl J Med Date: 2005-05-19 Impact factor: 91.245
Authors: Hiroshi Miyake; Takehiro Michikawa; Satsue Nagahama; Keiko Asakura; Yuji Nishiwaki Journal: Int J Environ Res Public Health Date: 2022-09-28 Impact factor: 4.614